These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32538348)

  • 1. Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle.
    Tadrous M; Ahuja T; Ghosh B; Kropp R
    Healthc Policy; 2020 May; 15(4):41-47. PubMed ID: 32538348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Canada Moving towards a More Agile Regulatory Approval and Reimbursement Process with a Shifting Role for Real-World Evidence (RWE) for Oncology Drugs?
    Lau CY; Rawson NSB
    Curr Oncol; 2024 Sep; 31(9):5599-5607. PubMed ID: 39330042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics.
    Klonoff DC
    J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
    Lau C; Jamali F; Loebenberg R
    J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Canadian Guidance for reporting real-world evidence for regulatory and health-technology assessment (HTA) decision-making.
    Tadrous M; Aves T; Fahim C; Riad J; Mittmann N; Prieto-Alhambra D; Rivera DR; Chan K; Lix LM; Kent S; Dawoud D; Guertin JR; McDonald JT; Round J; Klarenbach S; Stanojevic S; De Vera MA; Strumpf E; Platt RW; Husein F; Lambert L; Hayes KN
    J Clin Epidemiol; 2024 Dec; 176():111545. PubMed ID: 39322123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
    Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
    Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions.
    Akhras KS; Alsheikh-Ali AA; Kabbani S
    Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):245-250. PubMed ID: 30626231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid review: an emerging approach to evidence synthesis in health technology assessment.
    Khangura S; Polisena J; Clifford TJ; Farrah K; Kamel C
    Int J Technol Assess Health Care; 2014 Jan; 30(1):20-27. PubMed ID: 24451157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
    Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
    Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
    Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
    J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.